Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is The Hydration Pharmaceuticals Co EV-to-EBITDA?
The Hydration Pharmaceuticals CoASX:HPC EV-to-EBITDA is -1.41 as of Jul. 17, 2026. The stock has 3 warning signs investors should review. Among 272 Retail - Defensive companies, The Hydration Pharmaceuticals Co ranks worse than 367646.69% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, The Hydration Pharmaceuticals Co's enterprise value is A$5.88 Mil.
The Hydration Pharmaceuticals Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$-4.17 Mil. Therefore, The Hydration Pharmaceuticals Co's EV-to-EBITDA for today is -1.41.
The historical rank and industry rank for The Hydration Pharmaceuticals Co's EV-to-EBITDA or its related term are showing as below:
ASX:HPC'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -3.5 Med: -0.36 Max: 0.63
Current: -1.41
During the past 5 years, the highest EV-to-EBITDA of The Hydration Pharmaceuticals Co was 0.63. The lowest was -3.50. And the median was -0.36.
ASX:HPC's EV-to-EBITDA is ranked worse than 100% of 272
companies
in the Retail - Defensive industry
Industry Median: 8.52
vs ASX:HPC: -1.41
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
The Hydration Pharmaceuticals Co (ASX:HPC) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
The Hydration Pharmaceuticals Co's PE Ratio (TTM) for today is calculated as:
The Hydration Pharmaceuticals Co's share price for today is A$0.004.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. The Hydration Pharmaceuticals Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.011.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Hydration Pharmaceuticals Co EV-to-EBITDA Chart
ASX:HPC vs SYY, USFD, PFGC: EV-to-EBITDA Comparison
For the Food Distribution subindustry, The Hydration Pharmaceuticals Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Hydration Pharmaceuticals Co EV-to-EBITDA vs Retail - Defensive Industry
For the Retail - Defensive industry and Consumer Defensive sector, The Hydration Pharmaceuticals Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where The Hydration Pharmaceuticals Co's EV-to-EBITDA falls into.
The Hydration Pharmaceuticals Co's current Enterprise Value is A$5.88 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. The Hydration Pharmaceuticals Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$-4.17 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Hydration Pharmaceuticals Co (ASX:HPC) has a EV-to-EBITDA of -1.41 as of Jul. 17, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on The Hydration Pharmaceuticals Co. According to the industry distribution chart, The Hydration Pharmaceuticals Co ranks #999999 out of 272 companies in the Retail - Defensive industry.
Is The Hydration Pharmaceuticals Co's EV-to-EBITDA too high?
The Hydration Pharmaceuticals Co's current EV-to-EBITDA is -1.41. Based on the distribution chart, The Hydration Pharmaceuticals Co ranks #999999 out of 272 companies in the Retail - Defensive industry, which is in the bottom quartile relative to peers.
How does The Hydration Pharmaceuticals Co's EV-to-EBITDA compare to SYY and USFD?
According to the Retail - Defensive industry distribution chart, The Hydration Pharmaceuticals Co ranks #999999 out of 272 companies for EV-to-EBITDA. This places The Hydration Pharmaceuticals Co in the lower half of its industry. The industry median EV-to-EBITDA is 8.52. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Retail - Defensive company?
The median EV-to-EBITDA among Retail - Defensive companies is 8.52, based on 272 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on The Hydration Pharmaceuticals Co. For the Retail - Defensive industry, the median EV-to-EBITDA is 8.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Hydration Pharmaceuticals Co's current EV-to-EBITDA is -1.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Hydration Pharmaceuticals Co stock overvalued right now?
The Hydration Pharmaceuticals Co (ASX:HPC) has a current EV-to-EBITDA of -1.41. The current EV-to-EBITDA is -1.41. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For The Hydration Pharmaceuticals Co (ASX:HPC), the current EV-to-EBITDA is -1.41 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
The Hydration Pharmaceuticals Co Business Description
The Hydration Pharmaceuticals Co Ltd is a consumer products company that markets and sells a range of liquid, tablet and powder Healthy Hydration Solutions products into the USA market, under the Hydralyte brand. Hydralyte collates and translates consumer insights and needs into developing and delivering quality hydration products to market. The Company's business model is an asset light, flexible production model that allows it to outsource manufacturing and packaging to appropriate suppliers.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:HPC has been successfully added to your 
